GRAIL Inc GRAL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
GRAIL Reports Third Quarter 2026 Financial Results
GRAIL to Present at the UBS Global Healthcare Conference
7 healthcare stocks that stand out as investors pay up for the sector
7 healthcare stocks that stand out as -2-
GRAIL to Announce Third Quarter 2026 Financial Results
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test
Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
Trading Information
- Previous Close Price
- $121.35
- Day Range
- $114.00–122.00
- 52-Week Range
- $0.00–166.48
- Bid/Ask
- $114.78 / $118.00
- Shares Outstanding
- 44.96M
- Market Cap
- $5.21B
- Volume/Avg
- 361,128 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 30.49
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 910
- Website
- https://www.grail.com
Valuation
Metric | GRAL |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.11 |
Price/Sales | 30.49 |
Price/Cash Flow | — |
Price/Earnings
GRAL
Financial Strength
Metric | GRAL |
|---|---|
Quick Ratio | 8.56 |
Current Ratio | 8.93 |
Interest Coverage | — |
Quick Ratio
GRAL
Profitability
Metric | GRAL |
|---|---|
Return on Assets (Normalized) | −11.94% |
Return on Equity (Normalized) | −13.48% |
Return on Invested Capital (Normalized) | −14.03% |
Return on Assets
GRAL
Diagnostics & Research Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|^DK>^KMY | LOCK|dX^ | $259B | |||
| Danaher Corp DHR | LOCK|g$v#VlB | LOCK|K& | $164B | |||
| IDEXX Laboratories Inc IDXX | LOCK|qrdnw$< | LOCK|S<^ | $55B | |||
| Agilent Technologies Inc A | LOCK|q!n%F#Q | LOCK|m<f | $49B | |||
| Waters Corp WAT | LOCK|>Nx@^!p | LOCK|m^ | $45B | |||
| IQVIA Holdings Inc IQV | LOCK|t#<jRz^ | LOCK|ctqj> | $44B | |||
| Mettler-Toledo International Inc MTD | LOCK|>Qj<xBSc | LOCK|t!hw | $35B | |||
| Illumina Inc ILMN | LOCK|K$fDJy | LOCK|LSWGK | $31B | |||
| Labcorp Holdings Inc LH | LOCK|@zF#Swjc | LOCK|Pk&# | $30B | |||
| Quest Diagnostics Inc DGX | LOCK|<DQH>m | LOCK|#d%^y | $29B |
United States